Hypofractionation for prostate cancer and PROs
-
Published:2015-12
Issue:16
Volume:16
Page:1570-1571
-
ISSN:1470-2045
-
Container-title:The Lancet Oncology
-
language:en
-
Short-container-title:The Lancet Oncology
Reference10 articles.
1. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer; first results from MRC RT01 randomized controlled trial;Dearnaley;Lancet Oncol,2007
2. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer assessed with patient-reported outcomes: 2-year follow up of the randomised, non-inferiority, phase 3 CHHiP trial;Wilkins;Lancet Oncol,2015
3. Guidelines on prostate cancer,2015
4. Relationship of Ki-67 labeling index to DNA-ploidy, S-phase fraction, and outcome in prostate cancer treated with radiotherapy;Khoo;Prostate,1999
5. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy;Miralbell;Int J Radiat Oncol Biol Phys,2012